©The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Nov 14, 2016; 22(42): 9288-9299
Published online Nov 14, 2016. doi: 10.3748/wjg.v22.i42.9288
Published online Nov 14, 2016. doi: 10.3748/wjg.v22.i42.9288
Glycoproteins and glycoproteomics in pancreatic cancer
Sheng Pan, Teresa A Brentnall, Ru Chen, Department of Medicine, University of Washington, Seattle, WA 98195, United States
Author contributions: Pan S wrote the manuscript; Chen R and Brentnall TA reviewed and contributed to the manuscript.
Conflict-of-interest statement: The authors declare no conflict of interests for this article.
Correspondence to: Sheng Pan, PhD, Department of Medicine, University of Washington, 1959 NE Pacific St., Seattle, WA 98195, United States. shengp@medicine.washington.edu
Telephone: +1-206-6853632 Fax: +1-206-6859478
Received: June 29, 2016
Peer-review started: June 30, 2016
First decision: August 8, 2016
Revised: August 23, 2016
Accepted: September 14, 2016
Article in press: September 14, 2016
Published online: November 14, 2016
Processing time: 136 Days and 11.4 Hours
Peer-review started: June 30, 2016
First decision: August 8, 2016
Revised: August 23, 2016
Accepted: September 14, 2016
Article in press: September 14, 2016
Published online: November 14, 2016
Processing time: 136 Days and 11.4 Hours
Core Tip
Core tip: Protein glycosylation plays an important role in pancreatic tumorigenesis. Malignance induced changes in protein glycosylation can profoundly impact the function of a protein in multiple ways. One approach for developing better diagnostic and therapeutic strategies in pancreatic cancer involves targeting cancer-associated aberrant glycosylation. This review discusses the recent discoveries in glycoproteomics study of pancreatic cancer.